A modern Deltek Acumen Risk alternative

Acumen's Monte Carlo engine is mature and trusted, refined over many years of project-controls use. Acumen Fuse's 600+ metric library and DCMA 14-point automation are best-in-class for catching logic defects — missing predecessors, hard constraints, excessive lags, negative float — before they corrupt a risk model. That diagnostic depth, plus credibility with government and defense reviewers, is real and hard to replicate quickly.

If your work is owner- or government-grade EPC and aerospace project controls, and your reviewers expect DCMA/GAO/NASA-flavored forensic schedule diagnostics, Acumen is a defensible, well-understood choice. We are not going to pretend otherwise.

Acumen Risk / Fuse is quote-only enterprise software, oriented to Windows and desktop project-controls workflows, and shaped around construction and defense scheduling conventions. There is no self-serve price you can buy in an afternoon, and the UX assumes a trained controls analyst rather than a VP of Development or a deep-tech founder who needs an answer before a board meeting.

Crucially, Acumen ships only the Critical Path Method plus Monte Carlo. It has no Critical Chain (CCPM), no Theory of Constraints or Drum-Buffer-Rope, no decision gates with retroactive rescheduling, and no integrated WSJF / Cost of Delay — the techniques R&D programs lean on when resources are constrained and gate decisions, not just logic links, drive the timeline.

Its AI assistant, Dela, is the clearest gap. By design, Dela shares only context and metadata with the model — not the actual schedule. So it cannot tell you which specific task is driving your P80 slip, what a Go/No-Go gate does to downstream dates, or how a CMC vendor delay re-cascades the network. It assists around the schedule; it does not reason over it.

CritPath AI delivers the probabilistic core teams expect from Acumen — PERT-Beta Monte Carlo with risk-event injection, criticality index, tornado sensitivity, and P50/P80/P90 dates, with optional duration correlation — but pairs it with the full method stack. It computes the Critical Path Method (four dependency types, lag, float, near-critical), runs CCPM with Theory of Constraints and Drum-Buffer-Rope (drum, project and feeding buffers, fever chart), and treats decision gates (Go/No-Go/Pivot/Defer) as first-class schedule objects that retroactively reschedule the plan when a decision lands.

On top sits a Claude + Gemini copilot grounded in your real dependency graph. Because it reads the actual network — not just metadata — it can explain which task is consuming buffer, why a date moved, and what a gate or vendor slip does downstream. AACE RP 132R-23 Level 4 risk-driven scheduling with append-only audit trails gives pharma and federal teams a defensible record. It runs in a modern web app at $10/user/month, with AI usage billed separately by metered token cost plus margin.

Where CritPath is not yet a like-for-like swap: Acumen's Monte Carlo engine has far more years of validation, its schedule-quality metric library is broader and more forensic, and its DCMA/GAO/NASA credibility with government reviewers is something CritPath is still earning through lighthouse programs. Note too that 21 CFR Part 11 e-signatures, SOC 2 Type II, SAML SSO, HIPAA BAA, and on-prem are Enterprise / roadmap items, not shipped today, and autonomous AI-agent runs are off during the current beta (AI assistance — coach, decompose, reports, skill wizards — is on).

Choose Deltek Acumen if you run owner- or government-grade EPC, aerospace, or defense project controls, need exhaustive DCMA/GAO/NASA schedule-quality diagnostics, and have a trained analyst plus the budget for enterprise licensing. Acumen's depth in that lane is hard to beat.

Choose CritPath AI if you lead an R&D program — biotech IND timelines, deep-tech hardware, federally funded research — and need real Monte Carlo schedule risk plus CCPM, TOC, decision gates, and WSJF, with a copilot that actually reads your schedule and a modern, self-serve interface your whole team can use. That R&D-native quadrant, with rigorous risk math and a schedule-aware AI, is exactly where CritPath is built to win.